Phase 3 N=61 Efficacy and Safety Study of Caldolor (Intravenous Ibuprofen) in Hospitalized Adult and Pediatric Burn Patients
Burns
Primary: Temperature — 18.29; 12.21 Degree Celcius times hours (AUC-T)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=70 Safety and Efficacy of Deferasirox in Patients With Transfusion Dependent Iron Overload - a Non-comparative Extension Study
Liver Iron Overload
Primary: The Relative Change From Baseline in Liver Iron Content (LIC) After Prolonged Use of Deferasirox — -21.9; -23.1 Percent change
Phase 3 N=662 A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment
Hepatitis C, Chronic
Primary: Number of Participants With Sustained Virologic Response (SVR) 24 Weeks After the Last Planned Dose of Study Medication - SVR24 Planned — 171; 175; 22 Participants…
Phase 3 N=755 A Study to Evaluate Rituximab in Combination With Methotrexate in Methotrexate-Naive Patients With Active Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Change From Baseline in Modified Total Sharp Score (mTSS) From Screening at Week 52 — 1.079; 0.646; 0.359 Score on a scale — p=0.0016
Phase 3 N=1,200 Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years
Healthy Subjects
Primary: Percentage of Participants Achieving Predefined Serotype-specific Immunoglobulin G (IgG) Antibody Concentration Greater Than or Equal to (≥) 0.35 Micrograms Per…
Phase 3 N=4,292 Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults
Orthomyxoviridae Infection · Influenza · Myxovirus Infection
Primary: Geometric Mean Titers (GMTs) at Baseline and Post-vaccination With Either Fluzone Intradermal or Fluzone Intramuscular Vaccines — 23.50; 25.27; 25.29; 24.84 Titer
Phase 3 N=267 Efficacy and Safety of TMS for the Preemptive Treatment of Migraine With Aura
Migraine With Aura
Primary: Percentage of Participants Experiencing no Pain at Two Hours Post-treatment — 39; 22 percentage of participants
Phase 3 N=119 Effects Of Pregabalin (Lyrica) On Sleep Maintenance In Subjects With Fibromyalgia
Fibromyalgia · Sleep Disorders
Primary: Wake After Sleep Onset (WASO) at Weeks 5 and 11 — 70.69; 51.54 Minutes — p=<0.0001
Phase 3 N=134 The Safety and Efficacy of the Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Back Pain.
Back Pain
Primary: Pain on the Average, Mean Change From Baseline Days 21-84 (Last Observation Carried Forward [LOCF]) — -1.01; -1.82; -1.92 Units on a scale — p=0.0350
Phase 3 N=60 A Study of the Safety and Efficacy of Infliximab(REMICADE ) in Pediatric Patients With Moderately to SeverelyActive Ulcerative Colitis
Ulcerative Colitis
Primary: The Number of Participants With Clinical Response at Week 8 — 44 Participants
Phase 3 N=21 Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects
Multiple Sclerosis
Primary: Percentage of Participants in the Main Subset With Overall Success Using the Avonex Single-Use Autoinjector — 89 percentage of participants
Phase 3 N=727 Comparing Vasopressin and Adrenaline in Patients With Cardiac Arrest
Cardiac Arrest
Primary: Survival to Hospital Discharge. — 8; 11 Participants
Phase 3 N=243 Efficacy and Safety of Cyclosporine A Microemulsion in Maintenance Patients With Chronic Plaque Psoriasis
Chronic Plaque Psoriasis
Primary: Number of Participants With Relapse Rate (Success or Failure), as Assessed by Psoriasis Area and Severity Index (PASI) Score — 87; 36; 73; 43 Participants
Phase 3 N=209 Multicenter, Safety Study Of Maraviroc
Acquired Immunodeficiency Syndrome · HIV Infection
Primary: Number of Participants With Grade 3 and Grade 4 Adverse Events (AEs) and Serious Adverse Events (SAEs) — 40; 9; 34 Participants
Phase 3 N=550 Study Evaluating the Efficacy and Safety of Etanercept and Methotrexate in Japanese Subjects With Rheumatoid Arthritis
Arthritis, Rheumatoid
Primary: Change From Baseline in Modified Total Sharp Score (mTSS) at Week 52 — 9.82; 5.19; 3.33 Scores on a scale — p=<0.0001